RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Research context
Osmotica Pharmaceuticals plc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Osmotica Pharmaceuticals plc is currently in a long term downtrend where the price is trading 34.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Osmotica Pharmaceuticals plc's total revenue sank by 42.4% to $35M since the same quarter in the previous year.
Its net income has dropped by 106.0% to $-55M since the same quarter in the previous year.
Finally, its free cash flow fell by 3042.7% to $-9M since the same quarter in the previous year.
Based on the above factors, Osmotica Pharmaceuticals plc gets an overall score of 1/5.